NO20054700L - Anvendelse av et fibrat og orlistat for behandling av fedme - Google Patents

Anvendelse av et fibrat og orlistat for behandling av fedme

Info

Publication number
NO20054700L
NO20054700L NO20054700A NO20054700A NO20054700L NO 20054700 L NO20054700 L NO 20054700L NO 20054700 A NO20054700 A NO 20054700A NO 20054700 A NO20054700 A NO 20054700A NO 20054700 L NO20054700 L NO 20054700L
Authority
NO
Norway
Prior art keywords
fibrate
orlistat
treatment
obesity
obese patients
Prior art date
Application number
NO20054700A
Other languages
English (en)
Norwegian (no)
Inventor
Alan Dunlap Edgar
Original Assignee
Fournier Lab Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fournier Lab Ireland Ltd filed Critical Fournier Lab Ireland Ltd
Publication of NO20054700L publication Critical patent/NO20054700L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dental Preparations (AREA)
NO20054700A 2003-03-13 2005-10-12 Anvendelse av et fibrat og orlistat for behandling av fedme NO20054700L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03290625A EP1457206A1 (de) 2003-03-13 2003-03-13 Kombinierte Verwendung von einem Fibrat und von Orlistat zur Behandlung von Obesitas
PCT/EP2004/004010 WO2004080450A2 (en) 2003-03-13 2004-03-12 Combined use of a fibrate and orlistat for the treatment of obesity

Publications (1)

Publication Number Publication Date
NO20054700L true NO20054700L (no) 2005-10-12

Family

ID=32749013

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054700A NO20054700L (no) 2003-03-13 2005-10-12 Anvendelse av et fibrat og orlistat for behandling av fedme

Country Status (18)

Country Link
US (1) US20070078179A1 (de)
EP (2) EP1457206A1 (de)
JP (1) JP4928256B2 (de)
CN (1) CN100562313C (de)
AT (1) ATE384520T1 (de)
AU (1) AU2004218938B2 (de)
BR (1) BRPI0408322A (de)
CA (1) CA2518205C (de)
DE (1) DE602004011486T2 (de)
DK (1) DK1601352T3 (de)
EA (1) EA009127B1 (de)
ES (1) ES2300750T3 (de)
IL (1) IL170519A (de)
MX (1) MXPA05009718A (de)
NO (1) NO20054700L (de)
PT (1) PT1601352E (de)
WO (1) WO2004080450A2 (de)
ZA (1) ZA200507227B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2617688C (en) * 2007-02-22 2015-08-18 Alpex Pharma S.A. Solid dosage formulations containing weight-loss drugs
EP2625968A1 (de) * 2007-09-12 2013-08-14 Københavns Universitet Zusammensetzungen und methoden zur verstärkung der hungerunterdrückung und zum reduzieren der verdaulichkeit der nichtfettenergiesättigung
US20120053172A1 (en) 2009-02-12 2012-03-01 Cooperatieve Mirzorg U.A. Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
AU2011240690C1 (en) * 2010-04-12 2014-11-06 Reata Pharmaceuticals Holdings, LLC Method of treating obesity using antioxidant inflammation modulators
MX336980B (es) 2010-12-21 2016-02-09 Senosiain S A De C V Lab Combinacion y composicion para el tratamiento de obesidad.
BR112015014739A2 (pt) * 2012-12-21 2017-07-11 Merck Patent Gmbh carbonato hidróxido de magnésio como excipiente em preparações farmacêuticas tendo liberação melhorada do ingrediente ativo

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) * 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
TW438784B (en) * 1997-08-29 2001-06-07 Ssp Co Ltd Triazole derivative or salt thereof and pharmaceutical composition for treating mycosis containing the same
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
CA2324801A1 (en) * 1999-11-10 2001-05-10 Andrew Gordon Swick Use of apo b secretion/mtp inhibitors and anti-obesity agents
JP2003523336A (ja) * 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
EP1424070A1 (de) * 2002-11-28 2004-06-02 Fournier Laboratories Ireland Limited Zusammensetzung von einem PPAR-alpha Agonisten und Metformin zur Senkung des Serumtriglyceridspiegels

Also Published As

Publication number Publication date
US20070078179A1 (en) 2007-04-05
CA2518205C (en) 2012-05-08
EP1457206A1 (de) 2004-09-15
ZA200507227B (en) 2006-11-29
JP4928256B2 (ja) 2012-05-09
DE602004011486T2 (de) 2009-01-15
DK1601352T3 (da) 2008-05-13
JP2006520365A (ja) 2006-09-07
AU2004218938A1 (en) 2004-09-23
ES2300750T3 (es) 2008-06-16
EA200501259A1 (ru) 2006-02-24
AU2004218938B2 (en) 2009-04-09
EP1601352A2 (de) 2005-12-07
WO2004080450A2 (en) 2004-09-23
MXPA05009718A (es) 2005-10-18
HK1083767A1 (en) 2006-07-14
CN1826108A (zh) 2006-08-30
CN100562313C (zh) 2009-11-25
CA2518205A1 (en) 2004-09-23
PT1601352E (pt) 2008-04-07
WO2004080450A3 (en) 2005-02-24
EA009127B1 (ru) 2007-10-26
EP1601352B1 (de) 2008-01-23
DE602004011486D1 (de) 2008-03-13
ATE384520T1 (de) 2008-02-15
IL170519A0 (en) 2006-10-05
IL170519A (en) 2010-12-30
BRPI0408322A (pt) 2006-03-14

Similar Documents

Publication Publication Date Title
DK1423381T3 (da) 17beta-hydroxysteroid-dehydrogenase type 3-inhibitorer til behandling af androgenafhængige sygdomme
NO20100477L (no) Anvendelse av risendronat til fremstilling av medikamenter for behandling og prevensjon av osteoporose
ATE423559T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und ppar modulatoren
NO20050607L (no) Fremgangsmate og innretning for tildeling av CO
DE60328797D1 (de) Blutbehandlungsgerät
ATE442148T1 (de) Kombinationstherapie durch glukoseresorptionshemmer und retinoid x rezeptorenmodulatoren
AU2003234257A1 (en) Combination of cyclooxygenase-2 inhibitors and thalidomide for the treatment of neoplasia
CY1109814T1 (el) Ενας συνδυασμος που περιεχει candesartan και rosuvastatin για τη θεραπευτικη αντιμετωπιση της αρτηριοσκληρυνσης
CY1113083T1 (el) Ασβεστιολυτικες ενωσεις
DK1258720T3 (da) Måleenhed og roterende ventil til anvendelse deri
DK1545548T3 (da) Anvendelsen af kombinationen af ciclesonid og antihistaminer til behandingen af allergisk rhinitis
NO20030233L (no) Fremgangsmåte for å finne forbindelser som er egnet for behandling og/ellerprofylakse av fedme
DK1353948T3 (da) Oplöselige biologiske analoge til bata-amyloidpeptid
NO20066059L (no) Kombinasjon av en selektiv noradrenalin reopptaksinhibitor og en PDEV-inhibitor
DK1530462T3 (da) 1-phenyl-2-dimethylaminomethylcyclohexanforbindelser til behandling af depressionssymtomer. smerte og inkontinens
NO20055450D0 (no) Kombinasjon av et analeptisk modafinili og en antidepressiv forbindelse for behandling av depresjon
DK1569634T3 (da) Anvendelse af en PPAR-agonist og metformin til behandling af fedme
DK1601352T3 (da) Kombineret anvendelse af et fibrat og orlistat til behandling af fedme
DE60325744D1 (de) Zubereitung zur behandlung des nasopharyngalen carcinom und verwendung derselben
GB2409655B (en) Treatment of fluids
NO20054020D0 (no) Medisin for forhindring og behandling av arterosklerose og hypertensjon
IS8138A (is) Gaboxadól til meðhöndlunar á þunglyndi og öðrum geðrænum truflunum
FR2838959B1 (fr) Bassin medical
NO20062138L (no) Anvendelse av ifenprodil i behandling av smerte
NO20012440D0 (no) Framgangsmåte for behandling av naturgass

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application